Revenue Performance - Revenue cycle management (RCM) revenues comprised 57% of the company's consolidated revenue for 2023[130]. - Total revenues for the first six months of 2024 were $168.0 million, a decrease of 2% from $170.9 million in the same period of 2023[147]. - RCM revenues increased by $10.8 million, or 11%, in the first six months of 2024, primarily due to the acquisition of Viewgol, which contributed $9.9 million[166]. - Total EHR revenue for the first six months of 2024 was $60.831 million, down from $74.464 million in the same period of 2023, representing a decrease of $13.633 million, or 18%[183]. - RCM segment revenues increased by $10.755 million, or 11%, to $107.146 million for the first six months of 2024 compared to $96.391 million in the same period of 2023[183]. Customer Retention and Growth - The company achieved a retention rate of 92.1% for its Acute Care EHR customers in 2023, with rates consistently in the mid-to-high 90th percentile since 2019[136]. - The annualized retention rate for the first half of 2024 was reported at 95.0%[136]. - The company aims to enhance its recurring revenue base to stabilize revenues and cash flows, focusing on customer retention and demand for subscriptions[137]. - The transition to a subscription-based recurring revenue model is a key component of the company's long-term growth strategy[127]. Financial Performance and Costs - Net loss for the first six months of 2024 was $7.6 million, a decrease of $7.8 million compared to the prior-year period[147]. - Net loss for the second quarter of 2024 was $5.0 million, compared to a net loss of $2.8 million in the second quarter of 2023[165]. - General and administrative expenses decreased by $0.2 million, or 1%, compared to the second quarter of 2023, driven by reductions in non-recurring severance costs[160]. - General and administrative expenses increased by $4.8 million, or 14%, compared to the first six months of 2023, driven by stock compensation and the acquisition of Viewgol[175]. - Total costs of revenue (exclusive of amortization and depreciation) decreased to 51% of revenues during the second quarter of 2024, down from 52% in the second quarter of 2023[155]. Tax and Cash Flow - The effective tax rate for the three months ended June 30, 2024, decreased to 29.6% from 36.8% in the same period of 2023[164]. - Effective tax rate for the first six months of 2024 improved to 32.9% from 141.2% in the same period of 2023, largely due to the R&D tax credit[179]. - Net cash provided by operating activities increased by $1.5 million, from $10.2 million for the six months ended June 30, 2023, to $11.7 million for the six months ended June 30, 2024, primarily due to improved working capital management[190]. - Net cash provided by investing activities increased by $23.3 million, with $11.1 million provided during the six months ended June 30, 2024, compared to $12.2 million used during the same period in 2023, mainly due to the sale of AHT which resulted in a net cash inflow of $21.4 million[191]. Debt and Financing - As of June 30, 2024, the company had $181.5 million in principal amount of indebtedness outstanding under credit facilities, with cash and cash equivalents of $7.7 million[188]. - The company made a draw of $41.0 million on the revolving credit facility for the Viewgol acquisition, leaving a remaining borrowing capacity of $40.6 million[189]. - As of June 30, 2024, the company had $58.1 million in principal amount outstanding under the term loan facility and $123.4 million under the revolving credit facility, with an average interest rate of 8.42%[195]. - The company had $181.5 million of outstanding borrowings under credit facilities as of June 30, 2024, with a potential annual interest expense change of approximately $1.9 million for a 100 basis point change in interest rates[207]. Market and Strategic Initiatives - The healthcare IT sector is anticipated to continue attracting investment due to its potential to improve safety, efficiency, and compliance with regulatory requirements[139]. - The company is implementing margin optimization initiatives, including organizational realignment and expanded use of offshore resources[144]. - The company expects additional pressure on margins due to the integration and ramp-up of Viewgol, acquired in October 2023[145]. - RCM bookings increased by $2.1 million, or 8%, in the first six months of 2024 compared to the same period in 2023, while cross-sell bookings decreased by $3.9 million, or 24%[203]. - EHR bookings increased by $2.5 million, or 34%, during the second quarter of 2024 compared to the second quarter of 2023, with Acute Care EHR bookings increasing by $3.1 million[204]. Regulatory and Legislative Risks - The company faces risks related to significant legislative and regulatory uncertainty in the healthcare industry[126]. - The company is required to maintain a minimum fixed charge coverage ratio of 1.25:1.00, which was amended to 1.15:1.00 for fiscal quarters ending March 31, 2024, through December 31, 2024[199].

Financial Performance - Total bookings for Q2 2024 reached $23.3 million, a 10.95% increase from $21.0 million in Q2 2023[2] - Total revenue for Q2 2024 was $84.7 million, slightly up from $84.6 million in Q2 2023[2] - Revenue Cycle Management (RCM) revenue was $54.1 million, representing 63.9% of total revenue, compared to $47.8 million in the same quarter last year[2] - GAAP loss per diluted share was $(0.34), compared to $(0.20) in Q2 2023[2] - Non-GAAP earnings per diluted share decreased to $0.16 from $0.40 year-over-year[2] - Adjusted EBITDA for Q2 2024 was $12.6 million, an increase from $11.2 million in Q2 2023[2] - TruBridge reported a net loss of $7,565,000 for Q2 2024, compared to a net income of $247,000 in Q2 2023[12] - Non-GAAP net income for Q2 2024 was $2,318,000, compared to $5,701,000 in Q2 2023, a decline of 59.3%[17] - Non-GAAP EPS for Q2 2024 was $0.16, down from $0.40 in Q2 2023, a decrease of 60.0%[17] - The company reported a net income margin of (6.0%) for Q2 2024, compared to (3.4%) in Q2 2023[16] Revenue Guidance - For Q3 2024, total revenue is expected to be between $82 million and $85 million[4] - Full year 2024 revenue guidance is reiterated at between $330 million and $340 million[4] - Adjusted EBITDA for the full year 2024 is expected to be between $45 million and $50 million[4] Asset and Liability Management - Total current assets decreased to $91,583,000 as of June 30, 2024, down from $111,455,000 at the end of 2023, reflecting a decline of approximately 18%[11] - Total liabilities decreased to $231,185,000 as of June 30, 2024, down from $247,804,000 at the end of 2023, representing a reduction of about 7%[11] - The total stockholders' equity decreased to $181,102,000 as of June 30, 2024, down from $186,618,000 at the end of 2023, reflecting a decline of approximately 3%[11] Cash Flow and Investments - Cash and cash equivalents increased to $7,709,000 at the end of Q2 2024, compared to $3,848,000 at the beginning of the period, marking a rise of about 100%[12] - The net cash provided by operating activities was $11,730,000 in Q2 2024, an increase from $10,190,000 in Q2 2023[12] - The company invested $9,324,000 in software development during Q2 2024, compared to $12,143,000 in Q2 2023[12] Segment Performance - Adjusted EBITDA for the RCM segment was $7,804,000 in Q2 2024, up from $5,682,000 in Q2 2023, indicating a growth of approximately 37%[15] - Total recurring revenues from EHR for Q2 2024 were $26,666,000, down from $33,742,000 in Q2 2023, representing a decrease of 20.9%[18] - Total EHR revenues for the first six months of 2024 were $60,831,000, compared to $74,464,000 for the same period in 2023, a decrease of 18.3%[18] Expenses - Interest expense for Q2 2024 was $4,151,000, up from $2,586,000 in Q2 2023, an increase of 60.5%[16] - Stock-based compensation for Q2 2024 was $1,501,000, compared to a negative $123,000 in Q2 2023[16] - Severance and other non-recurring charges for Q2 2024 were $4,586,000, down from $6,819,000 in Q2 2023, a decrease of 32.4%[16] Margins - Total adjusted EBITDA margin for Q2 2024 was 14.8%, compared to 13.3% in Q2 2023, an improvement of 1.5 percentage points[16] - The company emphasized a strong pipeline and positive outlook for the remainder of the year[3] - The company reported a significant gain on the sale of business amounting to $1,250,000 in Q2 2024[12]

Financial Performance - Total revenues for the three months ended March 31, 2024, were $83.247 million, a decrease of 3.4% compared to $86.233 million for the same period in 2023[193]. - Adjusted EBITDA for the three months ended March 31, 2024, was $9.454 million, down 35.4% from $14.643 million in the same period of 2023[194]. - The company recorded a net loss of $2.516 million for the three months ended March 31, 2024, compared to a net income of $3.084 million for the same period in 2023[194]. - Operating income for Q1 2024 was a loss of $1.458 million, compared to an operating income of $6.295 million in Q1 2023[230]. - Total expenses for Q1 2024 increased to $84.705 million, or 101.8% of total revenues, compared to $79.938 million, or 92.7% of total revenues in Q1 2023[230]. - Net loss for the first quarter of 2024 was $2.5 million, a decrease of $5.6 million from a net income of $3.1 million in the first quarter of 2023[267]. Revenue Segments - Revenue Cycle Management (RCM) segment generated $53.038 million in revenue, accounting for 57% of total consolidated revenue for 2023[201]. - RCM revenues increased by $4.4 million, or 9%, compared to the first quarter of 2023, driven by the acquisition of Viewgol, which contributed $4.7 million[247]. - Recurring EHR revenues decreased by $5.0 million, or 16%, in Q1 2024 compared to Q1 2023, driven by the sale of American HealthTech, Inc. and customer migration to SaaS arrangements[234]. - Acute Care EHR revenues decreased by $1.7 million in Q1 2024, attributed to a decline in support revenues due to customer migration and attrition from the Centriq platform[234]. - Non-recurring EHR revenues decreased by $2.1 million, or 58%, compared to the first quarter of 2023, reflecting a strategic shift towards increasing recurring revenues[260]. Strategic Initiatives - The company aims to enhance its recurring revenue base, which is crucial for stabilizing revenues and cash flows[206]. - The company plans to expand RCM services beyond its existing EHR customer base to drive long-term revenue growth[206]. - The company changed its corporate name to TruBridge, Inc. on March 4, 2024, reflecting its strategic shift towards RCM services[201]. - The shift towards a SaaS license model has increased from 12% of annual new acute care EHR installations in 2018 to 100% in 2023 and Q1 2024, impacting short-term revenue growth but benefiting long-term profitability[209]. Cost Management - Costs associated with EHR revenues decreased by $5.1 million, or 31%, in Q1 2024 compared to Q1 2023, due to payroll and software cost reductions following the sale of American HealthTech[236]. - The company plans to enhance margins through cost containment measures and increased operational efficiencies, despite anticipated margin pressure from the transition to SaaS arrangements[221]. - General and administrative expenses increased by $4.9 million, or 34%, compared to the first quarter of 2023, influenced by the acquisition of Viewgol and increased severance costs[252]. - Product development expenses increased by $2.3 million, or 28%, compared to the first quarter of 2023, due to increased costs related to migrating to a public cloud environment[263]. Cash and Debt Management - Cash and cash equivalents as of March 31, 2024, were $4.1 million, up from $3.8 million as of December 31, 2023, with remaining borrowing capacity under the revolving credit facility at $36.6 million[257]. - As of March 31, 2024, the company had $63.0 million in principal amount outstanding under the term loan facility and $123.4 million under the revolving credit facility[293]. - The average interest rate for the revolving credit facility was 8.42% as of March 31, 2024[293]. - A 100 basis point change in interest rate on borrowings would result in a change in interest expense of approximately $1.9 million annually[302]. - The required consolidated fixed charge coverage ratio was decreased from 1.25:1.00 to 1.15:1.00 for each fiscal quarter ending March 31, 2024, through December 31, 2024[294]. Market Trends - The healthcare industry is increasingly pressured to adopt value-based reimbursement models, which may boost demand for healthcare IT solutions[207]. - The company achieved a retention rate of 92.1% in 2023, with a slight decline to 91.1% in Q1 2024 due to increased attrition from non-flagship products[220]. Bookings and Backlog - Total bookings for the three months ended March 31, 2024, were $23.569 million, an increase from $19.847 million in the same period of 2023[299]. - RCM bookings increased by $2.3 million, or 19%, in Q1 2024 compared to Q1 2023, while cross-sell bookings decreased by $0.5 million, or 9%[283]. - As of March 31, 2024, the company had a twelve-month backlog of approximately $11 million for non-recurring system purchases and approximately $321 million for recurring payments under support and maintenance and RCM services[282]. Stock Activity - The company repurchased 41,000 shares of common stock at an average price of $8.33 during March 2024[324].

Financial Performance - Bookings for the first quarter of 2024 reached $23.6 million, an increase from $19.8 million in the same quarter of 2023[16] - Total revenue for the first quarter of 2024 was $83.2 million, down from $86.2 million year-over-year[16] - Revenue Cycle Management (RCM) revenue was $53.0 million, representing 63.7% of total revenue, compared to $48.6 million in the previous year[16] - GAAP loss per diluted share was $(0.17), a decrease from earnings of $0.21 per diluted share in the prior year[16] - Non-GAAP earnings per diluted share were $0.19, down from $0.58 year-over-year[16] - Adjusted EBITDA for the first quarter was $9.5 million, compared to $14.6 million in the same quarter of 2023[16] - Total revenues for Q1 2024 were $83,247 million, a decrease of 3% from $86,233 million in Q1 2023[22] - Revenue from RCM (Revenue Cycle Management) increased to $53,038 million, up 9.9% from $48,631 million in the previous year[22] - EHR (Electronic Health Records) revenue decreased to $28,022 million, down 20.5% from $35,191 million in Q1 2023[22] - Net loss for Q1 2024 was $(2,516) million, a significant decline from a net income of $3,084 million in Q1 2023[22] - Non-GAAP net income for Q1 2024 was $2,707 million, compared to $8,232 million in Q1 2023, with a non-GAAP EPS of $0.19[53] Guidance and Expectations - For the full year 2024, the company expects total revenue to be between $330 million and $340 million, revised from a previous range of $340 million to $350 million[17] - The adjusted EBITDA guidance for 2024 remains unchanged at $45 million to $50 million[17] - Adjusted EBITDA for Q2 2024 is expected to be between $8.0 million and $10.0 million[31] Expenses and Losses - Total expenses for Q1 2024 were $84,705 million, an increase of 6.5% compared to $79,938 million in Q1 2023[22] - Operating loss for Q1 2024 was $(1,458) million, compared to an operating income of $6,295 million in Q1 2023[22] - Total cash used in operating activities was $(2,034) million, compared to $9,473 million in the previous year[37] - The company reported a provision for credit losses of $500 million in Q1 2024, compared to a benefit of $(352) million in Q1 2023[37] Assets and Equity - Total current assets decreased to $91,904 million from $111,455 million at the end of 2023[36] - Total liabilities decreased to $231,744 million from $247,804 million at the end of 2023[36] - Stockholders' equity decreased to $184,673 million from $186,618 million at the end of 2023[36] - Cash and cash equivalents at the end of Q1 2024 were $4,115 million, down from $6,816 million at the end of Q1 2023[37] Strategic Focus - The company noted a strong position in profitability due to effective expense management despite the revenue guidance revision[16] - The company is focusing on capturing larger deals in its RCM business, which may introduce timing complexities in revenue recognition[16] - Subscription revenue increased to $5,532 million in Q1 2024, compared to $3,207 million in Q1 2023, marking a growth of 72%[39] - Total recurring revenues from EHR decreased to $26,492 million in Q1 2024 from $31,519 million in Q1 2023, a decline of 16%[43] - The company made a significant investment of $21,410 million in the purchase of a business during Q1 2024[37]

Financial Performance - Net income for 2022 decreased by $2.6 million to $15.9 million, or $1.08 per share, compared to $18.4 million, or $1.26 per share, for 2021 [294]. - Income before taxes decreased to $18.1 million in 2022, compared to $23.1 million in 2021 [291]. - The effective income tax rate for 2022 was 12%, down from 20% in 2021, due to lowered provision-to-return adjustments and tax-free gains [292]. - Net cash provided by operating activities decreased by $31.3 million from $32.4 million for 2022 to $1.1 million for 2023, largely due to a decrease in net income [311]. Goodwill and Impairment - The company recorded a goodwill impairment charge of $35.9 million in the fourth quarter of 2023, with $21.9 million associated with the Post-acute care EHR reporting unit [287]. - Goodwill impairment charges totaled $2.2 million for the Post-acute care EHR, $6.4 million for the Acute care EHR, and $7.6 million for the Patient Engagement reporting unit, significantly impacting consolidated net income for the year [348]. - As of December 31, 2023, remaining goodwill was $171.9 million, with potential future impairment charges posing a risk to operational results [349]. Revenue and Bookings - Adjusted EBITDA for the RCM segment increased by $7.0 million, or 25%, compared to 2021, driven by a revenue growth of 37% [296]. - EHR bookings during 2023 decreased by $5.0 million, or 13%, primarily due to a challenging decision environment for new Acute Care EHR system arrangements [307]. - Bookings for the Patient Engagement business unit decreased by $0.2 million in 2023 compared to 2022, remaining effectively flat [318]. - RCM bookings increased by $0.9 million, or 2%, in 2023 compared to 2022, with net-new bookings rising by $3.4 million, or 23% [329]. Cash and Borrowing - As of December 31, 2023, the company had cash and cash equivalents of $3.8 million and remaining borrowing capacity of $24.3 million under its revolving credit facility, a decrease from $7.0 million and $86.3 million respectively as of December 31, 2022 [285]. - The company had $199.6 million in outstanding borrowings under credit facilities with Regions Bank as of December 31, 2023 [365]. - A 100 basis point change in interest rates on borrowings would result in an annual change in interest expense of approximately $2.0 million [365]. Credit Agreement and Compliance - As of December 31, 2023, the company was not in compliance with the fixed charge coverage ratio required by the Amended and Restated Credit Agreement, leading to a one-time waiver being provided [314]. - The Fourth Amendment to the Amended and Restated Credit Agreement decreased the required consolidated fixed charge coverage ratio from 1.25:1.00 to 1.15:1.00 for each fiscal quarter ending March 31, 2024, through December 31, 2024 [314]. - The company is permitted to voluntarily prepay credit facilities at any time without penalty, following the removal of mandatory prepayment requirements [316]. Acquisitions - The company completed a $36.7 million acquisition of Viewgol in the fourth quarter of 2023, following a $43.4 million acquisition of HRG in the first quarter of 2022 [312]. - Viewgol, LLC, a wholly-owned subsidiary acquired in 2023, represents 9% of total assets and 1% of revenues in the consolidated financial statements as of December 31, 2023 [361]. Internal Controls - Management assessed the effectiveness of internal control over financial reporting as of December 31, 2023, and believes it maintained effective control [360]. - The company’s internal control over financial reporting received an unqualified opinion based on PCAOB standards as of December 31, 2023 [364]. - The estimated fair value for the RCM reporting unit exceeded its carrying value by 48% as of October 1, 2023 [352]. Financial Instruments - The company has not utilized derivative financial instruments to manage interest rate risks as of December 31, 2023 [341]. Product Development - Product development expenses decreased by $0.9 million, or 3%, as increased costs related to migrating to a public cloud environment were offset by a $5.6 million increase in product development labor capitalization costs [288].

Computer Programs and Systems (CPSI) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.61 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.88%. A quarter ago, it was expected that this healthcare information technology company would post earnings of $0.40 per share when it actually produced earnings of $0.45, delivering a surprise of 1 ...

Revenue Performance - Fourth quarter 2023 total revenue was $85.9 million, an increase of 3.2% compared to $83.2 million in Q4 2022[15] - Full year 2023 total revenue reached $339.4 million, up from $326.6 million in 2022, marking a 3.5% increase[15] - Revenue Cycle Management (RCM) revenue for Q4 2023 was $51.0 million, representing 60.7% of total recurring revenue and 59.3% of total revenue[15] - Full year 2023 RCM revenue was $193.9 million, accounting for 58.9% of total recurring revenue and 57.1% of total revenue[15] - Bookings for Q4 2023 were $26.0 million, up from $24.7 million in Q4 2022[15] - Revenue from RCM for Q4 2023 was $6,596 thousand, down from $8,824 thousand in Q4 2022[25] - EHR revenue increased to $5,506 thousand in Q4 2023 from $4,886 thousand in Q4 2022[25] - Total revenue for the twelve months ended December 2023 was $47,576 thousand, compared to $55,899 thousand for the same period in 2022[25] - Total revenues for the fourth quarter of 2023 were $85,868 million, an increase of 3.2% compared to $83,224 million in the same period of 2022[34] - Revenue Cycle Management (RCM) segment generated $50,956 million in Q4 2023, up from $45,670 million in Q4 2022, reflecting a growth of 5.6%[34] - Patient engagement revenue reached $1,500 million in Q4 2023, a decrease of 5.4% from $1,586 million in Q4 2022[34] Financial Metrics - Adjusted EBITDA for Q4 2023 was $12.0 million, a decrease of 9.1% from $13.2 million in Q4 2022[15] - Adjusted EBITDA for Q4 2023 was $11,984, a decrease from $13,228 in Q4 2022, resulting in an Adjusted EBITDA margin of 14.0% compared to 15.9% in the prior year[26] - The company expects Q1 2024 revenue to be in the range of $82 million to $84 million and adjusted EBITDA between $8.5 million and $9.5 million[6] - For the full year 2024, the company projects revenue between $340 million and $350 million, with adjusted EBITDA of $45 million to $50 million[6] Net Income and Loss - The company reported a GAAP loss per diluted share of $(2.92) for Q4 2023, compared to a loss of $(3.15) for the full year 2023[15] - Net income for 2023 was $(45,789) thousand, a significant decrease from $15,867 thousand in 2022[22] - Net loss per common share for Q4 2023 was $(2.92), a decline from a net income of $0.17 per share in Q4 2022[34] - The company reported a net loss of $(42,474) million for the year ended December 31, 2023, compared to a net income of $2,517 million for the previous year[34] - Non-GAAP net income for Q4 2023 was $5,129, compared to $8,710 in Q4 2022, with Non-GAAP EPS at $0.36, down from $0.61[26] Expenses and Impairments - Total expenses for Q4 2023 were $127,649 million, significantly higher than $78,958 million in Q4 2022, marking an increase of 62%[34] - Operating loss for Q4 2023 was $(41,781) million, compared to an operating income of $4,266 million in Q4 2022[34] - The company reported an impairment of goodwill amounting to $35,913 thousand in 2023, with no such impairment recorded in 2022[22] - The company reported an impairment of goodwill amounting to $35,913 in Q4 2023, with no such impairment recorded in Q4 2022[26] - The company incurred severance and other nonrecurring charges of $22,186 for the twelve months ended December 2023, significantly higher than $4,505 in the previous year[26] - Interest expense for the twelve months ended December 2023 was $11,776, compared to $5,267 in the previous year[26] Cash Flow and Investments - Total cash provided by operating activities decreased to $1,059 thousand in 2023 from $32,375 thousand in 2022[22] - Cash and cash equivalents at the end of the period were $3,848 thousand, down from $6,951 thousand at the beginning of the period[22] - The company experienced a net cash used in investing activities of $(60,110) thousand in 2023, compared to $(62,731) thousand in 2022[22] - Proceeds from the revolving line of credit increased to $67,023 thousand in 2023 from $48,000 thousand in 2022[22] - The company invested $23,059 thousand in software development in 2023, up from $19,097 thousand in 2022[22] Market Position and Challenges - The recent acquisition of Viewgol is expected to strengthen the company's market position and enhance financial health for community hospital partners[15] - The company highlighted ongoing challenges in the healthcare industry, including market saturation and regulatory uncertainties, which may impact future performance[32] - Management emphasized the importance of non-GAAP financial measures as indicators of operational strength and performance trends[30] Contract and Subscription Growth - The company achieved net new RCM contracts of $7,130 million in Q4 2023, up from $5,173 million in Q4 2022, representing a growth of 37.8%[39] - Subscription revenue for EHR in Q4 2023 was $5,596 million, slightly up from $5,191 million in Q4 2022, indicating a growth of 7.8%[39]

MOBILE, Ala.--(BUSINESS WIRE)--CPSI (NASDAQ: CPSI), a healthcare solutions company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on Thursday, February 29, 2024, after the market closes. The Company will host a conference call at 4:30 p.m. Eastern Time that same day. The live broadcast of CPSI’s conference call will be available online at the Company’s website, www.cpsi.com. The 30-day online replay will be available approximately an hou ...

MOBILE, Ala.--(BUSINESS WIRE)--CPSI (NASDAQ: CPSI), a healthcare solutions company, today announced that the Company is rebranding and changing its name to TruBridge, Inc. (“TruBridge”). In a strategic move to streamline its offerings, enhance its market presence and position the Company for future growth, the Company is consolidating its diverse portfolio of solutions under a unified identity. CPSI will officially transition to TruBridge on Monday, March 4, 2024, when its common stock will begin trading on ...

Computer Programs and Systems, Inc. (NASDAQ:CPSI) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Chris Fowler - President and Chief Executive Officer Matt Chambless - Chief Financial Officer Conference Call Participants George Hill - Deutsche Bank Jeff Garro - Stephens Operator Greetings, and welcome to the CPSI Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presen ...